摘要
目的探讨膀胱灌注透明质酸钠治疗间质性膀胱炎（IC）的有效性和安全性。方法46例IC患者行透明质酸钠膀胱灌注治疗，每次40mg。每周1次，连续灌注4周，改为每月1次，直到第6个月。观察用药前及用药1、3、6个月临床症状改善情况（每日排尿次数、最大排尿容量、尿痛程度评分）和O’Leary—Sant IC问卷表评分及生活质量评分（QOL）情况。并记录不良反应发生情况。采用SPSS 11．5软件行统计学处理，所有资料用薯x±s表示。结果患者用药前和用药1、3、6个月24h排尿次数分别为（29．96±8．81）、（19．91±8．76）、（15．63±3．70）、（14．44±8．22）次；最大排尿容量分别为（115．51±65．58）、（125．73±65．53）、（146．07±65．11）、（166．51±64．72）ml；疼痛程度评分分别为（6．47±1．31）、（4．44±1．29）、（3．33±1．30）、（2．13±1．06）分；O’Leary-Sant评分分别为（26．60±3．77）、（19．53±3．79）、（15．13±3．78）、（11．84±3．43）分；用药后各时间点的每日排尿次数、最大排尿容量、疼痛程度、O’Leary—Sant评分与用药前相比差异均有统计学意义（均P〈0．01）。用药前和用药1、3、6个月QOL分别为5．47±0．51、3．44±0．55、2．36±0．57、2．29±0．59，用药后各时点与用药前相比差异均有统计学意义（均P〈0．01），用药1和3个月时比较，差异有统计学意义（P〈0．01），但用药3、6个月时比较差异无统计学意义（P〉0．05）。46例中仅1例女性患者治疗中被诊断患有肝癌停止治疗，余患者均完成治疗。灌注透明质酸钠后患者生命体征均平稳，无局部刺激症状，无全身不良反应。结论透明质酸钠膀胱灌注治疗能有效缓解IC患者的临床症状，改善生活质量，患者耐受性及安全性好。
Objective To investigate the safety and efficacy of intravesical sodium hyaluronate therapy for the patients with interstitial cystitis （IC）. Methods Foryt-six patients with IC were involved in this six-month, prospective trial. All the 46 patients received intravesicat sodium hyaluronate therapy, 40 mg/50 ml, once a week for 4 weeks, then once a month for 5 months. Clinical symptoms （micturition frequency per day, maximal micturition volume and odynuria degree score）, O＇ Leary- Sant IC symptom and problem index, and quality of life score were assessed at baseline and then again after 1, 3 and 6 months of treatment. Side effects were recorded. Results The levels of micturition frequency per day at the baseline and after 1, 3 and 6 months of the treatment were 29.96 ± 8.81, 19. 91±8.76, 15. 63±3.70 and 14.44±8.22, respectively. Compared with the baseline, there were significant differences（P〈0.01）. The levels of maximal micturition volume at the baseline and after 1, 3 and 6 months of the treatment were 115. 51±65. 58, 125.73±65.53, 146. 07±65. 11 and 166. 51±64.72 ml, respectively. Compared with the baseline, there were significant differences（P〈 0.01）. The levels of odynuria degree score at the baseline and after 1, 3 and 6 months of the treatment were 6.47±1.31, 4.44±1.29, 3.33±1.30 and 2.13±1.06, respectively. Compared with the baseline, there were significant differences（P〈0.01）. The levels of O＇Leary-Sant IC symptom and problem index at the baseline and after 1, 3 and 6 months of the treatment were 26.60±3.77, 19.53± 3.79, 15.13±3.78 and 11.84±3.43, respectively. Compared with the baseline, there were significant differences（P〈0.01）. The levels of quality of life score at the baseline and after 1, 3 and 6 months of the treatment were 5.47±0.51, 3.44±0.55, 2.36±0.57 and 2.29±0.59, respectively. Compared with the baseline, there were significant differences （P〈 0. 01）. There was significant difference between 3-month treatment and 1-month treatment in the aspect of life quality score. But there was no significant difference between 6-month treatment and 3-month treatment in the aspect of life quality score. One female patient withdrawled because of liver cancer. The other patients had stable vital sign in the whole treatment. There were no adverse events and bladder irritation after intravesical sodium hyaluronate therapy. Conclusion Intravesical sodium hyaluronate therapy can effectively relieve clinical symptom of IC and improve IC patients quality of life and is well tolerated.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2009年第9期599-601,共3页
Chinese Journal of Urology
关键词
膀胱炎
间质性
透明质酸钠
Cystitis, interstitial
Sodium hyaluronate
